July 23, 2020 | A.B. Cavalcanti, F.G. Zampieri, R.G. Rosa, L.C.P. Azevedo, V.C. Veiga, A. Avezum, L.P. Damiani, A. Marcadenti, L. Kawano-Dourado, T. Lisboa, D.L.M. Junqueira, P.G.M. de Barros e Silva, L. Tramujas, E.O. Abreu-Silva, L.N. Laranjeira, A.T. Soares, L.S. Echenique, A.J. Pereira, F.G.R. Freitas, O.C.E. Gebara, V.C.S. Dantas, R.H.M. Furtado, E.P. Milan, N.A. Golin, F.F. Cardoso, I.S. Maia, C.R. Hoffmann Filho, A.P.M. Kormann, R.B. Amazonas, M.F. Bocchi de Oliveira, A. Serpa-Neto, M. Falavigna, R.D. Lopes, F.R. Machado, and O. Berwanger, for the Coalition Covid-19 Brazil I Investigators*
This study evaluated the safety and efficacy of hydroxychloroquine, alone or in combination with azithromycin, in hospitalized patients with mild-to-moderate Covid-19. A multicenter, randomized, open-label, controlled trial was conducted involving 667 patients, of whom 504 had confirmed Covid-19. Patients were randomly assigned to receive standard care, standard care plus hydroxychloroquine (400 mg twice daily), or standard care plus hydroxychloroquine plus azithromycin (500 mg once daily) for 7 days. The primary outcome was clinical status at 15 days, assessed using a seven-level ordinal scale. The results showed no significant difference in clinical status between the groups, with both hydroxychloroquine alone and hydroxychloroquine plus azithromycin showing no improvement compared to standard care. Additionally, there was an increased frequency of adverse events, including prolongation of the QT interval and elevation of liver enzyme levels, in patients receiving hydroxychloroquine. The study concluded that hydroxychloroquine, either alone or with azithromycin, did not improve clinical outcomes in patients with mild-to-moderate Covid-19.This study evaluated the safety and efficacy of hydroxychloroquine, alone or in combination with azithromycin, in hospitalized patients with mild-to-moderate Covid-19. A multicenter, randomized, open-label, controlled trial was conducted involving 667 patients, of whom 504 had confirmed Covid-19. Patients were randomly assigned to receive standard care, standard care plus hydroxychloroquine (400 mg twice daily), or standard care plus hydroxychloroquine plus azithromycin (500 mg once daily) for 7 days. The primary outcome was clinical status at 15 days, assessed using a seven-level ordinal scale. The results showed no significant difference in clinical status between the groups, with both hydroxychloroquine alone and hydroxychloroquine plus azithromycin showing no improvement compared to standard care. Additionally, there was an increased frequency of adverse events, including prolongation of the QT interval and elevation of liver enzyme levels, in patients receiving hydroxychloroquine. The study concluded that hydroxychloroquine, either alone or with azithromycin, did not improve clinical outcomes in patients with mild-to-moderate Covid-19.